The objectives of the OPUS clinical study are to test if cenerimod is effective in reducing the symptoms of SLE and collect the safety information related to the drug.
The OPUS clinical study is described as “double-blind”, which means that neither the participants nor their medical team will know if they are given cenerimod or a placebo [see glossary]. This will be decided at random by a computer.
The investigational drug is a tablet taken by mouth once per day, every day. Participants in the OPUS clinical study will keep taking their current SLE treatment as agreed with by their doctor. Participants will in addition receive the investigational drug or placebo.
At the end of the OPUS clinical study, participants may be offered the choice to join a clinical study where they can continue to receive cenerimod while being followed by their medical team for 1 to 3 years. Individuals joining this program will not need to take a placebo.
Philippines 
日本語 